Skip to main content
Signal8
Launch Terminal

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBPHealthcare
+0.00%$4.22
AH$4.22+0.00%vs close
Mkt Cap$81.91M
Float16.96M
O/S19.41M
Vol
$ Vol
RVOL
Inst Own71.2%
SI16.0%
Earnings
Dilution
Corbus Pharmaceuticals Holdings, Inc. logoNASDAQ:CRBP$4.22+0.00%
Upcoming Catalysts
  • CRB-913READOUT
    Cash runway at this date: 9mo
    Nov 15, 2026in 13 days8-K
Phase Distribution
10 lead-sponsored trials·3 active·4 completed
Phase 11
Phase 1/22
Phase 24
Phase 33
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

    Lenabasum 5 mg, Lenabasum 20 mg

    Diffuse Cutaneous Systemic Sclerosis

    Enrollment
    365
    Start
    Dec 2017
    Primary Completion
    May 2020
    Completion
    Dec 2020
    NCT03398837
  • Phase 3
    Completed

    Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

    Lenabasum 20 mg, Lenabasum 5 mg

    Dermatomyositis

    Enrollment
    176
    Start
    Dec 2018
    Primary Completion
    Mar 2021
    Completion
    Oct 2021
    NCT03813160
  • Phase 3
    Recruiting

    A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

    CRB-701, capcitabine

    Oropharyngeal Carcinoma (OPC)

    Enrollment
    260
    Start
    Sep 2026
    Primary Completion
    Dec 2027est.
    Completion
    Mar 2029est.
    NCT07768189
  • Phase 2
    Terminated

    Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

    JBT-101, Placebo

    Diffuse Cutaneous Systemic Sclerosis

    Enrollment
    42
    Start
    Aug 2015
    Primary Completion
    Oct 2016
    Completion
    Dec 2020
    NCT02465437
  • Phase 2
    Completed

    Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

    JBT-101 (lenabasum)

    Cystic Fibrosis

    Enrollment
    85
    Start
    Sep 2015
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02465450
  • Phase 2
    Terminated

    Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

    JBT-101, Placebo

    Dermatomyositis

    Enrollment
    22
    Start
    Jun 2015
    Primary Completion
    Aug 2017
    Completion
    Jan 2021
    NCT02466243
  • Phase 2
    Completed

    Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

    Lenabasum 20 mg, Lenabasum 5 mg

    Cystic Fibrosis

    Enrollment
    447
    Start
    Dec 2017
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT03451045
  • Phase 1/2
    Recruiting

    A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

    CRB-701, Anti-PD-1

    Solid Tumor, Adult

    Enrollment
    348
    Start
    Apr 2024
    Primary Completion
    Jan 2027est.
    Completion
    Jan 2027est.
    NCT06265727
  • Phase 1/2
    Recruiting

    First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

    CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody

    Solid Tumor

    Enrollment
    156
    Start
    Dec 2024
    Primary Completion
    Nov 2026est.
    Completion
    Dec 2026est.
    NCT06603844
  • Phase 1
    Completed

    A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

    CRB-913, Placebo

    Obese But Otherwise Healthy Participants

    Enrollment
    254
    Start
    Dec 2025
    Primary Completion
    Aug 2026
    Completion
    Aug 2026
    NCT07310901
Search ClinicalTrials.gov for “Corbus Pharmaceuticals Holdings”